ClinicalTrials.gg
CompletedNCT07835373Updated Sep 29, 2026

A-PRF AND HA AFTER IMPACTED THIRD MOLAR SURGERY

An interventional study of Advanced Platelet-Rich Fibrin and Sodium hyaluronate in Third Molar Surgery, sponsored by Inonu University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 19 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Inonu University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Aug 2025, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
19 Years to 29 Years
Sex
All
01

Study summary

This randomized controlled clinical trial evaluated the effects of advanced platelet-rich fibrin (A-PRF) and hyaluronic acid (HA) on healing after surgical removal of impacted mandibular third molars. Participants were assigned to one of three groups: A-PRF applied to the extraction socket, HA applied to the extraction socket, or a control group receiving no additional biomaterial. Postoperative pain, facial swelling, and maximum mouth opening were assessed during the first postoperative week. Radiographic bone healing was evaluated using fractal dimension and mean gray value measurements on panoramic radiographs obtained on postoperative days 7 and 90. The study aimed to determine whether A-PRF or HA could improve postoperative clinical recovery and radiographic bone healing compared with standard treatment alone.

02

Conditions studied

  • Third Molar Surgery

Keywords

  • Hyaluronic acid
  • impacted third molar
  • fractal analysis
  • Radiographic gray value
  • advanced platelet-rich fibrin
03

In context

Lead sponsor

Inonu University is the lead sponsor of 398 studies on the registry; 97 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 29 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients aged 19-29 years. (ASA) physical status I. Presence of an impacted mandibular third molar indicated for surgical removal. Ability and willingness to comply with the study procedures and follow-up visits.

Provision of written .

Exclusion criteria

Exclusion Criteria:

Smoking. Poor oral hygiene. Presence of acute infection in the surgical area. Presence of a cystic or tumoral lesion associated with the impacted tooth. Uncontrolled periodontal disease. Refusal to participate or withdrawal of consent. Use of analgesics or antibiotics within 12 hours before surgery. Surgical procedure lasting longer than 40 minutes.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    A-PRF Group

    Advanced platelet-rich fibrin (A-PRF) was applied to the extraction socket following surgical removal of the impacted mandibular third molar.

    Biological: Advanced Platelet-Rich Fibrin

  • Experimental
    Hyaluronic Acid Group

    One milliliter of 0.8% sodium hyaluronate gel was applied to the extraction socket following surgical removal of the impacted mandibular third molar.

    Drug: Sodium hyaluronate

  • No intervention
    Control Group

    No additional biomaterial was applied to the extraction socket following surgical removal of the impacted mandibular third molar. Participants received the same surgical procedure and standard postoperative care as the other groups.

Interventions

  • BiologicalAdvanced Platelet-Rich Fibrin

    Advanced platelet-rich fibrin (A-PRF) was prepared from autologous venous blood by centrifugation at 1500 rpm for 14 minutes. The resulting A-PRF membrane was placed into the extraction socket immediately after surgical removal of the impacted mandibular third molar.

  • One milliliter of 0.8% sodium hyaluronate gel was applied directly into the extraction socket immediately after surgical removal of the impacted mandibular third molar.

06

What researchers measure

Primary outcomes

  1. Fractal Dimension of the Extraction Socket

    Fractal dimension (FD) was used to evaluate the trabecular bone pattern within the extraction socket on digital panoramic radiographs. A standardized 32 × 32-pixel region of interest was selected at the center of the extraction socket, and FD was calculated using the box-counting method in ImageJ.

    Time frame: Postoperative days 7 and 90

Secondary outcomes

  1. Mean Radiographic Gray Value

    Mean radiographic gray value was measured within a standardized 32 × 32-pixel region of interest located at the center of the extraction socket on digital panoramic radiographs using ImageJ software.

    Time frame: Postoperative days 7 and 90

  2. Postoperative Pain

    Postoperative pain intensity was assessed using a visual analog scale (VAS).

    Time frame: Postoperative days 1, 3, and 7

  3. Postoperative Facial Swelling

    Facial swelling was assessed using standardized facial measurements obtained between predefined anatomical landmarks before surgery and during postoperative follow-up.

    Time frame: Baseline and postoperative days 1, 3, and 7

  4. Maximum Mouth Opening

    Maximum mouth opening was measured in millimeters as the maximum interincisal distance.

    Time frame: Baseline and postoperative days 1, 3, and 7

07

Study locations

1 site
  • Inonu University Faculty of Dentistry
    Malatya, Battalgazi 44200, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in the published article will be shared. These data will include demographic characteristics, group allocation, postoperative pain scores, facial swelling measurements, maximum mouth opening measurements, fractal dimension values, and mean radiographic gray values.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: The study will be prepared for publication as a manuscript within six months.

Access criteria: All individual participant data (IPD) and supporting information will be available after publication of the article.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Jun 2026, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Sep 22, 2026
StartActual
Aug 11, 2025
Primary completionActual
Jun 30, 2026
CompletionActual
Jun 30, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: data sharing statement
1 update, last Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Minor edits only
    + 1 other change: data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07835373
Lead sponsor
Inonu University
Responsible party
Hadi Nasrollahi (Research Assistant, Inonu University) — Principal investigator
First posted
Sep 22, 2026
Start date
Aug 11, 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Sep 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronic Acid

Start the discussion